XBiotech Inc. reported a net loss of $26.9 million for its fiscal fourth quarter ended December 31 2025, translating to a loss of 88 cents per share. The loss reflects the company’s ongoing investment in clinical development and manufacturing expansion, with operating expenses for the quarter rising to $45.3 million from $38.7 million in the prior quarter. Cash and cash equivalents stood at $125.6 million as of December 31 2025, providing a runway for upcoming milestones.
The company’s full‑year 2025 loss totaled $45.5 million, or $1.49 per share, a decline from the $38.5 million loss reported for 2024. R&D spending for the year reached $47.4 million, while general and administrative costs were $8.3 million, underscoring the pre‑revenue nature of the business and the heavy focus on pipeline development.
Management highlighted progress in its oncology, dermatology, and infectious disease programs. The company noted that the Q4 results do not alter its long‑term growth trajectory or strategic focus, as it continues to advance antibody candidates that target interleukin‑1 alpha and other immune pathways.
The CEO’s retirement in 2025 added severance and bonus expenses that contributed to the higher operating costs for the quarter. Despite the loss, XBiotech’s cash position remains sufficient to fund near‑term development and facility expansion, with no revenue expected in 2026 due to the absence of product sales.
The company’s financials reflect a typical clinical‑stage profile: large losses driven by R&D investment, modest operating expenses relative to revenue (which is zero), and a cash balance that supports ongoing clinical milestones. Investors will view the Q4 loss as expected, while the continued pipeline progress and cash runway reinforce the company’s long‑term prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.